CLINICAL PROGNOSTIC FACTORS IN PRE- AND POST-MENOPAUSAL WOMEN WITH OVARIAN CARCINOMA.

Autor: Trifanescu OG; 'Prof. Dr. Al. Trestioreanu' Institute of Oncology, Radiotherapy 2, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania.; Department of Medical Oncology, Bucharest, Romania., Gales LN; 'Prof. Dr. Al. Trestioreanu' Institute of Oncology, Radiotherapy 2, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania.; Department of Medical Oncology, Bucharest, Romania., Trifanescu RA; Department of Endocrinology, Bucharest, Romania.; 'C. I. Parhon' Institute of Endocrinology, Department of Pituitary Pathology, Bucharest, Romania., Anghel RM; 'Prof. Dr. Al. Trestioreanu' Institute of Oncology, Radiotherapy 2, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania.; Department of Medical Oncology, Bucharest, Romania.
Jazyk: angličtina
Zdroj: Acta endocrinologica (Bucharest, Romania : 2005) [Acta Endocrinol (Buchar)] 2018 Jul-Sep; Vol. 14 (3), pp. 353-359.
DOI: 10.4183/aeb.2018.353
Abstrakt: Aims: To assess the impact of prognostic factors on the outcome of ovarian carcinoma (OC) and to determine the difference between pre and postmenopausal patients.
Design: Retrospective cohort, single centre study.
Subjects and Methods: One-hundred-sixty patients with stage IC-IV OC diagnosed between 2004-2016 were included. Treatment consisted in primary surgery followed by adjuvant chemotherapy (n=127, 79.4%), neoadjuvant chemotherapy followed by surgery (n=27, 16.9%) and chemotherapy alone (3.7%).
Results: At diagnosis 62 patients (38.8%) were premenopausal. Most patients presented with advanced OC (stage III/IV, 63.1%). After a median follow-up of 60 months, median progression free survival (PFS) for all stages was 36 months and median overall survival (OS) was 96 months. Postmenopausal patients had a poorer oncologic outcome compared with pre-menopausal women (PFS 24 vs. 72 months, p=0.0001, HR=2.32). Other clinical prognostic factors identified were performance status 1 vs . 0 (p=0.0001), ascites (p=0.027). Pathology prognostic factors were tumour grade (G1 vs . G2 and G3, p=0.0001) and endometrioid subtype compared to serous (p=0.008). Patients with residual disease after surgery had an increased risk of recurrence and death (HR=6.1, p=0.0001 and HR=4.2, p=0.0001).
Conclusion: Premenopausal patients had a better oncologic long-term outcome and stage, ascites, grading, residual disease, were independent prognostic factors.
Competing Interests: The authors declare that they have no conflict of interest.
Databáze: MEDLINE
Externí odkaz: